# Sleep-Disordered Breathing and Interactions with Opioids: A Narrative Review

## TL;DR

This paper reviews how opioid use interacts with sleep-disordered breathing, complicating treatment for chronic pain and sleep issues.

## Contribution

The paper provides a comprehensive review of the complex interactions between opioids and sleep-disordered breathing, emphasizing the need for multidisciplinary care.

## Key findings

- Opioids worsen sleep-disordered breathing by impairing respiratory drive and increasing apnea prevalence.
- Sleep-disordered breathing increases pain sensitivity, potentially affecting opioid efficacy and dosing.
- Multidisciplinary approaches, including enhanced screening and personalized treatment, are needed to manage this complex condition.

## Abstract

Opioid use in patients with sleep disordered breathing (SDB) presents therapeutic challenges within chronic pain and sleep medicine. Opioids impair respiratory drive through μ-opioid receptor activation in brainstem respiratory centers, exacerbating both obstructive and central apneas. Chronic opioid use is also linked to a high prevalence of central sleep apnea and increased nocturnal hypoventilation. Simultaneously, SDB contributes to heightened pain sensitivity via intermittent hypoxia, systemic inflammation, and alterations in neural plasticity. These mechanisms may influence opioid efficacy and dosing requirements. This review summarizes current evidence on how SDB and opioid use interact, emphasizing chronic opioid use in the setting of chronic pain management. We discuss the underlying mechanisms, clinical impacts, and potential avenues for enhanced diagnosis and therapy in this population. We conclude that the intersection of SDB and opioid use presents a complex clinical challenge that demands a multidisciplinary approach. Enhanced screening, personalized pharmacologic strategies, and integration of advanced diagnostics are essential for mitigating risks and optimizing care. Future research should focus on mechanistic studies and interventional trials to guide evidence-based management of this high-risk population.